Oncology PracticeAtezolizumab TNBC indication ‘in jeopardy’ because of phase 3 resultsSeptember 9, 2020Breast CancerMetastatic Breast Cancer
Oncology PracticePralsetinib: Second drug for RET+ NSCLC approved in U.S.September 8, 2020Lung Cancer
Hematology NewsFDA expands remdesivir use for all COVID-19 hospitalized patientsAugust 31, 2020COVID-19 Updates
Hematology NewsFDA approves clinical trials for cannabinoid drug designed to reduce COVID-19 lung inflammationAugust 25, 2020COVID-19 Updates
Oncology PracticeFDA updates hydrochlorothiazide label to include nonmelanoma skin cancer riskAugust 21, 2020Nonmelanoma Skin Cancer
Hematology NewsFDA approves belantamab in relapsed/refractory multiple myelomaAugust 6, 2020Multiple MyelomaLymphoma & Plasma Cell Disorders
Oncology PracticeEMA gives green light to avapritinib for GIST, acalabrutinib for CLLJuly 28, 2020GastroenterologyCLLLymphoma & Plasma Cell DisordersGastrointestinal Cancer
Hematology NewsFDA approves oral therapy for myelodysplastic syndromes, CMMLJuly 8, 2020Myelodysplastic SyndromeLeukemia, Myelodysplasia, Transplantation
Oncology PracticeUse of nonopioid pain meds is on the riseJuly 7, 2020Opioid Resource CenterPatient & Survivor Care
Oncology PracticeFDA approves avelumab as maintenance for urothelial carcinomaJuly 1, 2020Genitourinary CancerGynecologic Cancer
Oncology PracticeFDA approves new indications for pembrolizumabJuly 1, 2020Patient & Survivor CareBreast CancerCNS/Brain CancerGastroenterologyGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
Oncology PracticePembro approved for first-line use in MSI-H/dMMR colorectal cancerJune 30, 2020GastroenterologyGI OncologyGastrointestinal Cancer
